Statins, Fibrates and Myopathy: pathophysiological mechanism, risk factors and laboratory markers / Estatinas, Fibratos e Miopatia: mecanismos fisiopatológicos, fatores de risco e marcadores laboratoriais

Maria Fernanda Camargo Barbosa de Barros, Manuela Bianchini Silva, Beatriz Marques da Silva, Laura Cruz de Siqueira Franco, Gabriel Drigo Camacho, Pablo Luiz Carvalho dos Santos, Matheus Dinelli de Oliveira, Marina Okada Xandó de Oliveira, Amanda do Nascimento e Silva, Fabiana Gaspar Gonzalez, Edgar Matias Bach Hi

Abstract


With the increasing life expectancy of the world population, the elderly experiences the occurrence of multiple chronic diseases, a phenomenon called multimorbidity. Such condition induces the need for the elderly to engage in combined pharmacological treatments, giving rise to polypharmacy, leading to the often unnecessary and inadequate consumption of some drugs. Among these, we can mention fibrates and statins, widely used in the control and treatment of dyslipidemia. Both classes of drugs present as the main adverse effect of concern the genesis of myalgias and myositis, with evolution to rhabdomyolysis. In view of the above, this study aimed to understand the mechanism responsible for inducing muscle damage in the administration of these drugs, also considering the factors that favor their appearance and the laboratory markers used for diagnostic purposes. This work was carried out from a bibliographic review using scientific articles published in English, Portuguese and Spanish, available in the PubMed, Scielo, LILACS and Google academic databases.


Keywords


statins, fibrates rhabdomyolysis, miopathy, hypolipemiants, muscle damage

References


Melo LAd, Lima KCdJC, Coletiva S. Prevalência e fatores associados a multimorbidades em idosos brasileiros. 2020;25:3869-77.

Gorard DAJQAijoM. Escalating polypharmacy. 2006;99(11):797-800.

Pereira KG, Peres MA, Iop D, Boing AC, Boing AF, Aziz M, et al. Polifarmácia em idosos: um estudo de base populacional. 2017;20:335-44.

Secoli SR, Marquesini EA, Fabretti SdC, Corona LP, Romano-Lieber NSJRBdE. Tendência da prática de automedicação entre idosos brasileiros entre 2006 e 2010: Estudo SABE. 2019;21.

Werlang MC. Impacto da intervenção farmacêutica na adesão à prescrição médica por idosos em tratamento para dislipidemia. 2006.

Cavalcante JS, Reis HSP, de Souza NZ, de Carvalho Hott R. ESTATINAS E AS DISLIPIDEMIAS: IMPORTÂNCIA DO TRATAMENTO E O RISCO DE MIOPATIAS. 2020.

Best O, Gnjidic D, Hilmer SN, Naganathan V, McLachlan AJJImj. Investigating polypharmacy and drug burden index in hospitalised older people. 2013;43(8):912-8.

Cervellin G, Comelli I, Benatti M, Sanchis-Gomar F, Bassi A, Lippi GJCb. Non-traumatic rhabdomyolysis: background, laboratory features, and acute clinical management. 2017;50(12):656-62.

Cabral BMI, Edding SN, Portocarrero JP, Lerma EVJD-a-M. Rhabdomyolysis. 2020;66(8):101015.

Aleckovic-Halilovic M, Pjanic M, Mesic E, Storrar J, Woywodt A. From quail to earthquakes and human conflict: a historical perspective of rhabdomyolysis. Clinical Kidney Journal. 2020;14(4):1088-96. doi: 10.1093/ckj/sfaa075 %J Clinical Kidney Journal.

Oliveira FLd. Rabdomiólise: revisão bibliográfica com base num caso clinico de etiologia rara 2016.

Chavez LO, Leon M, Einav S, Varon JJCc. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. 2016;20(1):1-11.

Raposo JN, João A, Namora J, Carvalho AJMI. Rabdomiólise-breve revisão, a propósito de um caso. 2002;9(1):80-4.

Costa RR, Vieira AF, Coconcelli L, Fagundes AdO, Buttelli ACK, Pereira LF, et al. Uso de Estatinas Melhora a Proteção Cardiometabólica Promovida pelo Treinamento Físico em Ambiente Aquático: Um Ensaio Clínico Randomizado. 2021;117:270-8.

Ribeiro LO, R. DESVENDANDO O PARADIGMA DAS GORDURAS SATURADAS E DO COLESTEROL PARTE 5: Estatinas e seus Efeitos Colaterais. Brazilian Journal of Surgery and Clinical Research – BJSCR. 2020;33:24.

Faludi AA, Izar MCdO, Saraiva JFK, Chacra APM, Bianco HT, Afiune A, et al. Atualização da diretriz brasileira de dislipidemias e prevenção da aterosclerose–2017. 2017;109:1-76.

Xavier HT, Izar M, Faria Neto J, Assad M, Rocha V, Sposito A, et al. V Diretriz brasileira de dislipidemias e prevenção da aterosclerose. 2013;101:1-20.

Fonseca FAHJAbdc. Pharmacokinetics of statins. 2005;85:9-14.

Carvalho MHCd, Mancini MC, Melo MEd, Bahia LR, Negrão CE, Matos LDNJd, et al. I Diretriz brasileira de diagnóstico e tratamento da síndrome metabólica. 2005.

Xavier HTJABdC. Farmacologia do fibratos. 2005;85:15-6.

Magalhães MECJABdC. Mechanisms of rhabdomyolysis with statins. 2005;85:42-4.

Sirtori CRJPr. The pharmacology of statins. 2014;88:3-11.

Matos CMS. Utilização terapêutica das estatinas: indicações, novas perspetivas e efeitos laterais a curto e longo prazo 2019.

Furberg CD, Pitt BJT. Withdrawal of cerivastatin from the world market. 2001;2(5):1-3.

L Catapano AJCvp. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin. 2012;10(2):257-67.

Horodinschi R-N, Stanescu AMA, Bratu OG, Pantea Stoian A, Radavoi DG, Diaconu CCJM. Treatment with statins in elderly patients. 2019;55(11):721.

Hirota T, Fujita Y, Ieiri IJEOoDM, Toxicology. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. 2020;16(9):809-22.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. 2019;39(2):e38-e81.

Ward NC, Watts GF, Eckel RHJCR. Statin toxicity: mechanistic insights and clinical implications. 2019;124(2):328-50.

Thompson PD, Clarkson PM, Rosenson RSJTAjoc. An assessment of statin safety by muscle experts. 2006;97(8):S69-S76.

Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. 2004;292(21):2585-90.

Harper CR, Jacobson TAJCoil. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. 2007;18(4):401-8.

Baker SK, Samjoo IAJCjons. A neuromuscular approach to statin-related myotoxicity. 2008;35(1):8-21.

Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. 2004;200(3):237-50.

Kalra SJEP. The role of Coenzyme Q10 in statin-associated myopathy. 2009;1:2-8.

Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger MJJoP, Therapeutics E. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. 2005;314(3):1032-41.

Dirks AJ, Jones KMJAJoP-CP. Statin-induced apoptosis and skeletal myopathy. 2006;291(6):C1208-C12.

Pierno S, Didonna M, Cippone V, De Luca A, Pisoni M, Frigeri A, et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. 2006;149(7):909-19.

Koch A, Pereira R, Machado MJJMNI. The creatine kinase response to resistance exercise. 2014;14(1):68-77.

Syrovatkina V, Alegre KO, Dey R, Huang X-YJJomb. Regulation, signaling, and physiological functions of G-proteins. 2016;428(19):3850-68.

Apostolopoulou M, Corsini A, Roden MJEjoci. The role of mitochondria in statin‐induced myopathy. 2015;45(7):745-54.

Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, et al. Statin therapy and plasma coenzyme Q10 concentrations—A systematic review and meta-analysis of placebo-controlled trials. 2015;99:329-36.

Deichmann R, Lavie C, Andrews SJOJ. Coenzyme q10 and statin-induced mitochondrial dysfunction. 2010;10(1):16-21.

Larsen S, Stride N, Hey-Mogensen M, Hansen CN, Bang LE, Bundgaard H, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. 2013;61(1):44-53.

Gurha N, Rehan HS, Yadav M, Gupta LKJCN, Neurosurgery. Association of statin induced reduction in serum coenzyme Q10 level and conduction deficits in motor and sensory nerves: An observational cross-sectional study. 2020;196:106046.

Ros E, Laguna JCJREdCS. Tratamiento de la hipertrigliceridemia: fibratos frente a ácidos grasos omega-3. 2006;6(4):52D-61D.

Zhou J, Li D, Cheng QJM. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. 2020;99(21).

Jakob T, Nordmann AJ, Schandelmaier S, Ferreira‐González I, Briel MJCDoSR. Fibrates for primary prevention of cardiovascular disease events. 2016;(11).

Motojima K, Seto KJB, Bulletin P. Fibrates and statins rapidly and synergistically induce pyruvate dehydrogenase kinase 4 mRNA in the liver and muscles of mice. 2003;26(7):954-8.

Hodel CJTl. Myopathy and rhabdomyolysis with lipid-lowering drugs. 2002;128(1-3):159-68.

Yildiz A, Gucuk E, Cay SJAc. A case of rhabdomyolysis and tromboembolic event secondary to fibrate monotherapy. 2008;63(4):515-7.

Wu J, Song Y, Li H, Chen JJEjocp. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. 2009;65(12):1169-74.

Forcadell-Peris M, de Diego-Cabanes CJS-MdF. Rabdomiolisis secundaria a simvastatina y fenofibrato. 2014;40(4):e91-e4.

Davidson MH, Armani A, McKenney JM, Jacobson TAJTAjoc. Safety considerations with fibrate therapy. 2007;99(6):S3-S18.

Mastaglia F, Needham MJCn, reports n. Update on toxic myopathies. 2012;12(1):54-61.

Strauss V, Mellert W, Wiemer J, Leibold E, Kamp H, Walk T, et al. Increased toxicity when fibrates and statins are administered in combination–a metabolomics approach with rats. 2012;211(2):187-200.

Neuvonen PJ, Niemi M, Backman JTJCP, Therapeutics. Drug interactions with lipid‐lowering drugs: mechanisms and clinical relevance. 2006;80(6):565-81.

Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JHJDM, et al. Effects of fibrates on metabolism of statins in human hepatocytes. 2002;30(11):1280-7.

Santos PGJCeIeA. Combinaciones de estatinas y fibratos: implicaciones farmacocinéticas y clínicas. 2014;26:7-11.

Garrison DA, Talebi Z, Eisenmann ED, Sparreboom A, Baker SDJP. Role of OATP1B1 and OATP1B3 in drug-drug interactions mediated by tyrosine kinase inhibitors. 2020;12(9):856.

Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. 2002;301(3):1042-51.

Jacobson TA, Zimmerman FHJTJoCH. Fibrates in combination with statins in the management of dyslipidemia. 2006;8(1):35-41.

Thompson PD, Clarkson P, Karas RHJJ. Statin-associated myopathy. 2003;289(13):1681-90.

Camerino GM, Pellegrino MA, Brocca L, Digennaro C, Camerino DC, Pierno S, et al. Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle. 2011;81(8):1054-64.

Klawitter J, Shokati T, Moll V, Christians U, Klawitter JJBcr. Effects of lovastatin on breast cancer cells: a proteo-metabonomic study. 2010;12(2):1-20.

Holt S, Moore KJIcm. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. 2001;27(5):803-11.

Efstratiadis G, Voulgaridou A, Nikiforou D, Kyventidis A, Kourkouni E, Vergoulas GJH. Rhabdomyolysis updated. 2007;11(3):129.

Cabral GG, Monice LM, Machado LRD, Caldeira LML, Roquim L, de Araujo Couto HJABB. Insuficiência renal aguda devido à rabdomiólise. 2012;3(2):42-7.

Russell TAJNnj. Acute renal failure related to rhabdomyolysis: pathophysiology, diagnosis, and collaborative management. 2005;32(4).

Giannoglou GD, Chatzizisis YS, Misirli GJEjoim. The syndrome of rhabdomyolysis: pathophysiology and diagnosis. 2007;18(2):90-100.

Foschini D, Prestes J, Charro MAJRbdcedh. Relação entre exercício físico, dano muscular e dor muscular de início tardio. 2007;9(1):101-6.




DOI: https://doi.org/10.34117/bjdv8n6-244